November 14, 2014 — Men with prostate cancer will be the first group of patients in China to benefit from the recent clearance of Elekta's Clarity soft tissue visualization system by the China Food and Drug Administration (CFDA). As part of Elekta's premiere linear accelerator offering, Versa HD, Clarity enables clinicians to use non-ionizing ultrasound technology to non-invasively image the prostate and surrounding soft tissues before patients begin treatment.
The authorization for Clarity use in China follows the CFDA's clearance in September of Elekta's Versa HD linear accelerator, enabling Elekta to sell and market the system in China.
According to the International Agency for Research on Cancer, well over 3 million people are diagnosed with cancer every year in China. Prostate cancer is the sixth most common cancer for men in China.
For more information: www.elekta.com
April 10, 2024 
